FASTBASE has developed QF-Pro®, a transformative bio-imaging platform that precisely quantifies protein-protein interactions and protein post-translational modifications in patient pathology samples and cell lines, with an unprecedented degree of specificity, sensitivity, and insight to tumor heterogeneity.

Unveiling these molecular phenomena in the TME provides with a new family of biologically relevant informative biomarkers based on protein function and opens whole new avenues for improving the precision medicine agenda.